Literature DB >> 21922652

Neuroblastoma progress on many fronts: the Neuroblastoma Research Symposium.

Luke Wylie1, Anna Philpott.   

Abstract

Neuroblastoma (NBL) is a pediatric tumor of infancy derived from precursor cells of the sympathetic nervous system. Clinicians and researchers in developmental biology and genetics recently met to facilitate meaningful crosstalk and to discuss considerable progress made in the clinical treatment and basic biology of NBL. For instance, discoveries in familial NBL have identified genetic aberrations in Phox2b and Alk that predispose to NBL, while advances in epigenetics and MYCN regulation have also offered insight into NBL pathogenesis and future treatment. Moreover, novel therapeutic avenues are also being explored, including targeted immunotherapies, and innovative radiotherapeutic and chemotherapeutic approaches. This multi-disciplinary meeting was convened to aid the transfer of new biological findings into the clinic and to use clinical advances to inform the basic biological understanding of this devastating disease.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21922652      PMCID: PMC3243773          DOI: 10.1002/pbc.23329

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  18 in total

1.  Germline PHOX2B mutation in hereditary neuroblastoma.

Authors:  Yael P Mosse; Marci Laudenslager; Deepa Khazi; Alex J Carlisle; Cynthia L Winter; Eric Rappaport; John M Maris
Journal:  Am J Hum Genet       Date:  2004-10       Impact factor: 11.025

2.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 3.  Immunotherapy for neuroblastoma: turning promise into reality.

Authors:  Juliet C Gray; Janice A Kohler
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

4.  Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons.

Authors:  Tobias Reiff; Konstantina Tsarovina; Afsaneh Majdazari; Mirko Schmidt; Isabel del Pino; Hermann Rohrer
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

5.  MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.

Authors:  P Mestdagh; E Fredlund; F Pattyn; J H Schulte; D Muth; J Vermeulen; C Kumps; S Schlierf; K De Preter; N Van Roy; R Noguera; G Laureys; A Schramm; A Eggert; F Westermann; F Speleman; J Vandesompele
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

6.  The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.

Authors:  Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

8.  DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

Authors:  Tina Branscombe Miranda; Connie C Cortez; Christine B Yoo; Gangning Liang; Masanobu Abe; Theresa K Kelly; Victor E Marquez; Peter A Jones
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

9.  Modelling Myc inhibition as a cancer therapy.

Authors:  Laura Soucek; Jonathan Whitfield; Carla P Martins; Andrew J Finch; Daniel J Murphy; Nicole M Sodir; Anthony N Karnezis; Lamorna Brown Swigart; Sergio Nasi; Gerard I Evan
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

10.  Identification of ALK as a major familial neuroblastoma predisposition gene.

Authors:  Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.